Xenon Pharmaceuticals (XENE) Change in Acquisitions & Divestments (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $98.5 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $98.5 million, down 40.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.2 million (down 30.74% YoY), and the FY2025 annual result was $574.5 million, down 17.98% from the prior year.
• Change in Acquisitions & Divestments eased to $98.5 million in Q1 2026 per XENE's latest filing, from $123.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $235.7 million in Q2 2024 and troughed at $20.3 million in Q1 2022.
• A 5-year average of $136.6 million and a median of $136.9 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments slumped 55.87% in 2022, then surged 674.7% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $104.8 million in 2022, then surged by 30.66% to $136.9 million in 2023, then advanced by 21.01% to $165.6 million in 2024, then fell by 25.19% to $123.9 million in 2025, then dropped by 20.51% to $98.5 million in 2026.
• Business Quant data shows XENE's Change in Acquisitions & Divestments at $98.5 million in Q1 2026, $123.9 million in Q4 2025, and $113.5 million in Q3 2025.